I. Delaet

651 total citations
16 papers, 515 citations indexed

About

I. Delaet is a scholar working on Rheumatology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, I. Delaet has authored 16 papers receiving a total of 515 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 8 papers in Genetics and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in I. Delaet's work include Rheumatoid Arthritis Research and Therapies (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). I. Delaet is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). I. Delaet collaborates with scholars based in United States, Belgium and Germany. I. Delaet's co-authors include Peter Nash, R. Pappu, Sheila Gujrathi, Rieke Alten, Jeffrey Kaine, Mark C. Genovese, Allison Luo, Edward Keystone, Charles Ludivico and Michael E. Weinblatt and has published in prestigious journals such as Annals of the Rheumatic Diseases, Virology and Trends in Microbiology.

In The Last Decade

I. Delaet

15 papers receiving 490 citations

Peers

Countries citing papers authored by I. Delaet

Since Specialization

Citations

This map shows the geographic impact of I. Delaet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Delaet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Delaet more than expected).

Fields of papers citing papers by I. Delaet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Delaet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Delaet. The network helps show where I. Delaet may publish in the future.

Co-authorship network of co-authors of I. Delaet

This figure shows the co-authorship network connecting the top 25 collaborators of I. Delaet. A scholar is included among the top collaborators of I. Delaet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Delaet. I. Delaet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Long‐Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment 2014 ·Arthritis & Rheumatology ·Rieke Alten, Jeffrey Kaine, Edward Keystone, Peter Nash, I. Delaet, Mark C. Genovese	50
2	Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data 2013 ·The Journal of Rheumatology ·Edward Keystone, Mark C. Genovese, Mark S. Hochberg, Roger B. Cohen, Michael E. Weinblatt, Jeffrey Kaine, Peter Nash, I. Delaet, (unknown)	1
3	Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program 2013 ·The Journal of Rheumatology ·Michael E. Weinblatt, Larry W. Moreland, René Westhovens, Roger B. Cohen, Sheila Kelly, Nader Khan, R. Pappu, I. Delaet, Allison Luo, Sheila Gujrathi, Marc C. Hochberg	104
4	SAT0128 Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data 2013 ·Annals of the Rheumatic Diseases ·Rieke Alten, Marc C. Hochberg, Rachel Cohen, Michael E. Weinblatt, Jeffrey Kaine, E. Keystone, Peter Nash, I. Delaet, Mark C. Genovese	0
5	Safety profile of subcutaneous abatacept focusing On clinically relevant events in patients with rheumatoid arthritis and up to 4.5 years of exposure 2012 ·Queensland's institutional digital repository (The University of Queensland) ·Rieke Alten, Jeffrey Kaine, Edward Keystone, Peter Nash, I. Delaet, (unknown), Mark C. Genovese	3
6	Efficacy, safety and pharmacokinetics of subcutaneous abatacept in patients with rheumatoid arthritis, with or without an intravenous loading dose 2012 ·Lara D. Veeken ·Peter Nash, Charles Ludivico, I. Delaet, (unknown), Bindu Murthy, M Corbo, Jeffrey Kaine	4
7	Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study 2012 ·Annals of the Rheumatic Diseases ·Edward Keystone, Joel M. Kremer, Anthony S. Russell, J. Box, Carlos Abud‐Mendoza, Mario Alberto Garza‐Elizondo, Allison Luo, Richard Aranda, I. Delaet, René Swanink, Sheila Gujrathi, Michael E. Luggen	43
8	Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel‐Arm, Open‐Label Study 2012 ·Arthritis Care & Research ·Peter Nash, S. Nayiager, Mark C. Genovese, Alan Kivitz, Kurt Oelke, Charles Ludivico, William Palmer, (unknown), I. Delaet, Ayanbola Elegbe, M Corbo	61
9	FRI0191 Immunogenicity is low and transient with intravenous abatacept therapy 2012 ·Annals of the Rheumatic Diseases ·Michael E. Weinblatt, Mark C. Genovese, Michael Schiff, René Westhovens, Rieke Alten, I. Delaet, Marleen Nys, Jessica E. Manning, J.M. Kremer	2
10	FRI0193 SC vs IV abatacept in RA: post-hoc efficacy analysis of long-term acquire (SC) data with aim (IV) data 2012 ·Annals of the Rheumatic Diseases ·M. C. Genovese, (unknown), (unknown), G. Léon, Eduardo Mysler, M. Keiserman, R. Valente, Peter Nash, Jesus Abraham Simón Campos, J. Box, Clarence W. Legerton, Е. Л. Насонов, Patrick Durez, I. Delaet, Ayanbola Elegbe, Rieke Alten	2
11	AB0567 Safety of SC abatacept in patients with ra: Update from pooled clinical trial data 2012 ·Annals of the Rheumatic Diseases ·(unknown), Jeffrey Kaine, E. Keystone, Peter Nash, I. Delaet, Karen Qi, Mark C. Genovese	5
12	Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study) 2011 ·Annals of the Rheumatic Diseases ·Jeffrey Kaine, (unknown), Ingrid Strusberg, (unknown), Ingrid Louw, Sheila Gujrathi, R. Pappu, I. Delaet, Miranda Pans, Charles Ludivico	63
13	Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate 2011 ·Arthritis & Rheumatism ·(unknown), (unknown), G. Léon, Eduardo Mysler, M. Keiserman, R. Valente, Peter Nash, (unknown), W. Porawska, Jeffrey Box, Clarence W. Legerton, E L Nasonov, Patrick Durez, R. Aranda, R. Pappu, I. Delaet, J. Teng, Rieke Alten	155
14	Capsid destabilization is required for antibody-mediated disruption of poliovirus 1994 ·Journal of General Virology ·I. Delaet, Albert Boeyé	8
15	Antibody neutralization of picornaviruses: can fever help? 1994 ·Trends in Microbiology ·Albert Boeyé, I. Delaet, (unknown)	6
16	Antigenic N to H conversion of poliovirus by a monoclonal antibody at low ionic strength 1992 ·Virology ·I. Delaet, R. Vrijsen, Albert Boeyé	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact